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Haemophilus influenzae type b (Hib) remains the principal cause
of invasive bacterial diseases in under 5-year-olds in
developing countries.1-3 In those few developing countries
where Hib vaccines are being used, the vaccines have proven
to be effective in reducing transmission rates and protecting
children at risk from invasive Hib diseases.4,5
South Africa introduced universal Hib vaccination into the
Expanded Programme on Immunisation (EPI) in July 1999.6 A
recent pre-immunisation study,7 conducted in Cape Town,
indicated that Hib accounted for 86.5% of all the H. influenzae
cases, 97.3% of meningitis cases, 71.4% of pneumonia cases and
50% of septicaemia cases.7 The incidence rates for all invasive
Hib infections were found to be 169 and 47 per 100 000
population for children < 1 and < 5 years, respectively.7 These
figures are no different from those in many other developing
countries where there is a high burden of Hib diseases.3, 4
Hib vaccines contain a capsular polysaccharide, polyribosyl-
ribitol phosphate (PRP), which is the major virulence factor,2
and a target for eliciting protective antibodies (anti-PRP)
against Hib disease.8-10 Current Hib vaccines contain
polysaccharide antigens chemically conjugated to a carrier
protein (derived from either Corynebacterium diphtheriae,
Clostridium tetani, or N. meningitidis) to enhance their
immunogenicity and boost immunological memory.11-13
South Africa has adopted the World Health Organisation
(WHO)'s accelerated 4-week interval immunisation schedule,
whereby children are vaccinated against polio, diphtheria-
tetanus-pertussis, hepatitis B and Hib diseases at the ages of 6,
10 and 14 weeks.  In this study, we evaluated the safety and
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Objectives. Haemophilus influenzae type b (Hib) infection
remains a major public health problem in the developing
world. We evaluated the safety and immunogenicity of a new
PRP-CRM197 conjugate Hib vaccine (Vaxem Hib, Chiron
Vaccines), compared with the HibTITER vaccine (Wyeth-
Lederle Vaccines), following the World Health Organisation
(WHO)'s accelerated schedule which allows 4-week intervals
between doses.
Study design. A phase II, observer-blind, multicentre,
randomised, controlled, non-inferiority study.
Methods. In total, 331 babies were immunised with either
Vaxem Hib (N = 167) or HibTITER (N = 164) vaccine at 6, 10
and 14 weeks of age, in parallel with oral polio, diphtheria-
tetanus-pertussis and hepatitis B vaccines.  Post-
immunisation reactions were recorded after each
immunisation and at follow-up visits.  Anti-polyribosyl-
ribitol phosphate (PRP) antibodies were measured using
enzyme-linked immunosorbent assays (ELISAs) before and 1
month after the third immunisation.
Results. Overall, there was no significant difference in the
anti-PRP levels between the two groups.  One month after the
third immunisation, 76% of vaccinees in the Vaxem Hib
group and 70% in the HibTITER group had anti-PRP
antibody titres ≥ 1.0 µg/ml, while 96% of the Vaxem Hib
group and 90% of the HibTITER group demonstrated anti-
PRP antibody titres ≥ 0.15 µg/ml.  The geometric mean titre
at day 90 was 3.77 µg/ml for the Vaxem Hib and 3.0 µg/ml
for the HibTITER groups.  Although the Vaxem Hib vaccine
produced more redness (6% versus 1%; p = 0.006) and
swelling (5% versus 1%, p = 0.037), overall it was well
tolerated compared with the HibTITER vaccine.  There was
no significant difference in vaccine-related elevated
temperature (≥ 38°C) between the two groups (p = 0.11).
Conclusion. Both vaccines showed comparable safety and
immunogenicity profiles when administered to South African
babies at 6, 10 and 14 weeks of age.
S Afr Med J 2004; 94: 43-46.
Department of Community Health, Medical University of Southern Africa, Pretoria 
Maila J Matjila, MB ChB, MMed (Comm Health)
Department of Microbiology, Medical University of Southern Africa, Pretoria 
Thabo C Phohu, BSc Med Hons
Anwar A Hoosen, MB ChB, MMed (Microbiol)
Chiron Vaccines, Clinical Research and Medical Affairs, Chiron Behring GmbH &
Co, Marburg, Germany
Angelika Banzhoff, MD
Chiron Vaccines, Clinical Research and Medical Affairs, Chiron S.r.I., Siena, Italy
Simonetta Viviani, MD
Massimo Bianchini, PhD
Pantaleo Nacci, MSc
Audino Podda, MD
Department of Paediatrics and Child Health, Medical University of Southern
Africa, Pretoria
Chapman W Palweni, MB ChB, MMed, FCP (SA)
Department of Family Medicine, Medical University of Southern Africa, Pretoria
Michael Whitfield, MRCS, DCH, MRCGP, DPH, FRCGP
Clinical Research Centres South Africa (Pty) Ltd, Pretoria, Gauteng
Sanet Aspinall, PhD
44
January 2004, Vol. 94, No. 1  SAMJ
ORIGINAL ARTICLES
immunogenicity of a new PRP-CRM197 conjugate Hib vaccine
(Vaxem Hib, Chiron Vaccines), compared with the HibTITER
vaccine (Wyeth-Lederle Vaccines), following the WHO's
accelerated immunisation schedule (4-week intervals between
doses). 
Materials and methods
Study design and study area
This was a phase II, observer-blind, multicentre, randomised,
controlled, non-inferiority study, conducted in three different
clinics: Phedisong 1 (Ga-Rankuwa), Hebron (Hebron) and
Boekenhout (Mabopane), all of which are situated north-west
of Pretoria, South Africa.
Vaccines
The investigational vaccine was the Hib b conjugate vaccine,
Vaxem Hib (Chiron Vaccines, Siena, Italy). The chemistry of
this vaccine was based on controlled hydrolysis of the PRP
polysaccharide to oligosaccharides, followed by selective
activation of the reducing end and subsequent coupling to the
carrier protein, through an adipic acid spacer.14 The non-toxic
mutant of diphtheria toxin, CRM197, was used as a protein
carrier.  In the final vaccine formulation, aluminium hydroxide
was used as an adjuvant. 
The pre-clinical and clinical development of this vaccine
showed a high level of tolerability and immunogenicity,14,15 and
allowed it to be registered for use in infants and children under
the age of 12 months, with an 8-week interval between doses.
Each dose of Vaxem Hib contains 10 µg of capsular
oligosaccharide of Hib conjugated to approximately 25 µg of
carrier protein, mutant diphtheria CRM197, and the final
formulation contains 0.05 mg of thiomersal, 1 mg of aluminium
hydroxide and sodium phosphate buffer (pH = 7) in a 0.5 ml
volume. 
The comparative vaccine was the American Home Product
HibTITER vaccine (Wyeth-Lederle Vaccines, USA).  Each 0.5 ml
dose contains 10 µg of purified Hib capsular antigen and
approximately 25 µg of diphtheria CRM197 protein conjugate,
dissolved in 0.9% sodium chloride.  The HibTITER is indicated
for the immunisation of babies and children aged 6 weeks - 5
years, against Hib diseases.  The HibTITER vaccine has the
same carrier protein, CRM197, as the Vaxem Hib vaccine, but
lacks the aluminium hydroxide adjuvant in the final
formulation.
Ethics and consent
The study protocol was approved by the Research and Ethics
Committee of the Faculty of Medicine of the Medical
University of Southern Africa (MEDUNSA) and the Medicines
Control Council of South Africa.  Parents or legal guardians of
the subjects were adequately informed of the study, and only
babies of parents and legal guardians who signed consent
forms were recruited into the study. 
Subjects’ enrolment and selection criteria
A total of 331 healthy South African babies who were
candidates for primary vaccination according to the EPI
schedule were recruited, and received either Vaxem Hib
vaccine (N = 167, 89 male and 78 female, mean age 47.5 days),
or HibTITER vaccine (N = 164, 77 male and 87 female, mean
age 47.4 days).   Subjects were included if they were 6 - 8
weeks of age and in good health, as determined by medical
history, physical examination and clinical assessment.
Vaccination protocols
Each of the study vaccines was injected intramuscularly in the
anterolateral muscle of the right thigh.  The other routine infant
EPI vaccines (i.e. diphtheria-tetanus-pertussis (DTwP), hepatitis
B vaccine (HBV) and oral polio vaccine (OPV)), were
administered concomitantly, but separately, following standard
procedures.  DTwP was given as an intramuscular injection in
the anterolateral muscle of the left thigh, HBV was
administered in the right deltoid region, and OPV was given
orally.
Randomisation and blinding
Randomisation was done using a 1:1 ratio and was stratified by
immunisation centre.  To ensure observer blinding, only
designated unblinded study staff who had no access to the
study subjects or to their records had access to the
randomisation list for vaccine assignment.  The unblinded staff
were instructed not to reveal (except in an emergency) the
identity of the study vaccines to the parents or legal guardians
or to the other blinded personnel (investigator, study nurse,
etc.) involved in monitoring or conducting the study.
Evaluating post-immunisation reactions
Babies were observed for signs and symptoms of local or
systemic reactions at the clinic (30 minutes after each of the
three vaccine administrations) by the study personnel and at
home (2 - 3 days after immunisation) by the parent or legal
guardian and/or study nurse at follow-up visits.  
Laboratory methods
Collection of specimens
Samples of venous blood (2 - 3 ml) for antibody assays were
drawn before the first immunisation and 4 - 6 weeks after the
third immunisation.  The clotted blood was stored at 2 - 8°C
and centrifuged within 12 hours.  Serum samples were stored
at –20°C until shipped in dry ice to Chiron laboratories, Siena,
Italy. 
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Measurement of serum antibody titres 
The anti-PRP antibody assays were performed at the Chiron
laboratories, Siena, Italy, using a modified enzyme-linked
immunosorbent assay (ELISA) technique.16 The Food and Drug
Administration (FDA) standard reference sera, with known
antibody titres, were used.  Measures of immunogenicity were
anti-PRP antibody titres ≥ 0.15 µg/ml (for protection) and ≥ 1.0
µg/ml (for long-lasting protection).
Statistical methods
This was designed as a non-inferiority study, adequately
powered to exclude differences in percentage of subjects with
post-immunisation anti-PRP titres ≥ 1.0 µg/ml greater than
15% by means of a two-sided 90% confidence interval (CI).17
Descriptive statistics (mean, standard deviation, median,
minimum and maximum) were calculated.  Incidences of local
and systemic reactions were compared between vaccine groups
using the chi-square test, or Fisher's exact test.  The geometric
mean titres (GMTs) and 95% CIs were calculated by
exponentiating (base 10) the least squares means of the
logarithmically transformed (base 10) titres and their 95% CIs
obtained from a one-way analysis of variance (ANOVA) with
factor for vaccine group. The geometric mean ratios (GMRs)
and 90% CIs were calculated by exponentiating the difference
between the least squares means and the associated 90% CI
from the same ANOVA.
Results
Immunisations schedules
Initially, 167 babies received Vaxem Hib vaccine and 164
received HibTITER vaccine.  However, 17 subjects (10%) in the
Vaxem Hib group were eventually excluded after receiving the
first dose, 4 because of initial inappropriate enrolment and 13
because they were lost to follow-up.  Similarly, 32 subjects
(20%) in the HibTITER group were eventually excluded, for
several reasons: 24 because they were lost to follow-up, 6
because of protocol deviation or inappropriate initial
enrolment, 1 due to an adverse event, and 1 because of
withdrawal of consent.  Therefore, a total of 150 subjects (90%)
in the Vaxem Hib group and 132 subjects  (80%) in the
HibTITER group completed the immunisation protocols, and of
these babies, 143 (86%) in the Vaxem Hib group and 126 (77%)
in the HibTITER group were included in the immunogenicity
analyses (Fig. 1). 
Primary and secondary post-immunisation response
At baseline there was no significant difference between study
subjects with anti-PRP antibody titres ≥ 1.0 µg/ml in the two
groups (14% v. 15%) in the subset of babies evaluated for
immunogenicity (Fig. 1).  At day 90, 1 month after the third
immunisation, 76% of vaccinees in the Vaxem Hib group and
70% of those in the HibTITER group demonstrated a titre ≥ 1.0
µg/ml, and this difference was not statistically significant.
Since the lower limit of the CI was well above the pre-specified
value of –15% (90% CI: –3% - 15%), non-inferiority was
demonstrated.
At baseline there was a significant imbalance for both
percentage of subjects with anti-PRP titres ≥ 0.15 µg/ml and
anti-PRP GMT, with higher values in the HibTITER group.
After vaccination, the Vaxem Hib vaccine group was slightly
more immunogenic when anti-PRP antibody titres ≥ 0.15
µg/ml were used as a measure 1 month after the last dose.  It
was found that 96% in the Vaxem Hib group and 90% in the
HibTITER group had anti-PRP antibody titres ≥ 0.15 µg/ml 
1 month after the third immunisation in the same subset of
subjects evaluated for immunogenicity (Fig. 1).  Moreover, the
post-vaccination GMT for the Vaxem Hib group was 3.77
µg/ml and 3.0 µg/ml for the HibTITER group, and the 90% CI
for their ratio included 1, i.e. the difference was not statistically
significant.  The ratio of Vaxem Hib vaccine to HibTITER
vaccine GMRs was 1.77 (90% CI: 1.1 - 2.85). 
Post-immunisation reactions
In both vaccine groups, local and systemic reactions were mild
and transient and resolved without sequelae.  Although the
Vaxem Hib vaccine produced more redness (6% versus 1%, 
p = 0.006) and swelling (5% versus 1%, p = 0.037) than the
HibTITER vaccine, overall it was well tolerated.  Finally, 6% of
subjects in the Vaxem Hib group demonstrated a post-
vaccination fever (temperature ≥ 38°C) versus 2% in the
HibTITER group, which was not statistically significant 
(p = 0.11).  
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Fig. 1. Primary (anti-PRP ( 1.0 µg/ml) and secondary (anti-PRP 
≥ 0.15 µg/ml) immunogenicity measures.
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Discussion
The widespread application of Hib conjugate vaccines in the
USA has resulted in the decline of the number of reported Hib
invasive cases by 99% between 1987 and 1997.18 In The Gambia,
the efficacy of the conjugate vaccine was 95% for the
prevention of all invasive Hib diseases.4 These are encouraging
results and clearly demonstrate the feasibility of eliminating
Hib diseases through effective immunisation programmes.
However, significant reduction in childhood morbidity and
mortality from Hib diseases will only occur when vaccination
coverage rates with Hib conjugate vaccines have been achieved
in most of the developing world.  The major constraint on
introducing these vaccines is cost.  One study investigated the
potential of maximising the use of these vaccines in poorer
countries by diluting a Hib conjugate vaccine 10-fold in a
multidose vial of DTwP vaccine, and the diluted vaccine was
found to be as immunogenic and safe as the full dose.19
Many developing countries vaccinate infants according to
the WHO's accelerated 4-week interval schedule. An ideal Hib
conjugate vaccine for the developing world should be easily
integrated into this schedule, without compromising its
immunogenic potency, and should be compatible with other
childhood vaccines.  We found comparable immunogenicity
results for the Vaxem Hib vaccine and the HibTITER vaccine
for anti-PRP antibody titres ≥ 1.0 µg/ml before and after the
immunisation course, and non-inferiority of the Vaxem Hib
vaccine was demonstrated (Fig. 1).  However, overall the
Vaxem Hib vaccine was  slightly more immunogenic than the
HibTITER vaccine, perhaps due to aluminium hydroxide
adjuvant, which is not present in the HibTITER.  
Further, the Vaxem Hib vaccine was well tolerated, despite
producing slightly more redness and swelling at the site of
injection compared with the HibTITER vaccine.  Increased local
reaction at the injection site is a well-known and normal
consequence of an adjuvant,  in this case included in the Vaxem
Hib vaccine but not in the HibTITER vaccine.
In conclusion, Vaxem Hib and HibTITER vaccines
demonstrated comparable safety and immunogenicity profiles
when administered to South African infants at 6, 10 and 14
weeks of age.  Infants in countries such as South Africa with a
high endemicity of Hib invasive diseases need to be protected
with an optimal immunogenic vaccine in early childhood as
provided by the WHO accelerated immunisation schedule.
We thank staff members of Phedisong 1 clinic, Hebron clinic, and
Boekenhout clinic for their warmth and support. 
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